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Gilles de la Tourette Syndrome (TS) is a neurodevelopmental disorder marked by the
appearance of multiple involuntary motor and vocal tics. TS presents high comorbidity
rates with other disorders such as attention deficit hyperactivity disorder (ADHD) and
obsessive compulsive disorder (OCD). TS is highly heritable and has a complex polygenic
background. However, environmental factors also play a role in the manifestation of
symptoms. Different epigenetic mechanisms may represent the link between these two
causalities. Epigenetic regulation has been shown to have an impact in the development
of many neuropsychiatric disorders, however very little is known about its effects on
Tourette Syndrome. This review provides a summary of the recent findings in genetic
background of TS, followed by an overview on different epigenetic mechanisms, such
as DNA methylation, histone modifications, and non-coding RNAs in the regulation of
gene expression. Epigenetic studies in other neurological and psychiatric disorders are
discussed along with the TS-related epigenetic findings available in the literature to date.
Moreover, we are proposing that some general epigenetic mechanisms seen in other
neuropsychiatric disorders may also play a role in the pathogenesis of TS.
Keywords: Tourette Syndrome, genetics, epigenetics, DNA methylation, non-coding RNA, neurological disorders,
psychiatric disorders
INTRODUCTION
Gilles de la Tourette Syndrome (TS) is a neurodevelopmental disorder characterized by one vocal
and multiple motor tics, lasting longer than a year (Robertson, 2000). The prevalence of TS is
estimated to be ∼1% and it occurs more in males than females, with a ratio of 4 to 1, without
differences between social classes. Furthermore, in almost 90% of cases, TS arises along with
comorbid neuropsychiatric disorders: in 45–60%with obsessive-compulsive disorder (OCD), while
in 60% of cases with attention deficit hyperactivity disorder (ADHD). Anxiety, behavioral disorders,
autism spectrum disorders, and learning disabilities are also quite common among individuals with
TS (Baron-Cohen et al., 1999; Coffey et al., 2000; Kurlan et al., 2002; Burd et al., 2005; Robertson
and Orth, 2006; Cavanna and Termine, 2012; Robertson, 2012).
Tics are defined as sudden movements or vocalizations that are recurrent, rapid, arrhythmic,
and stereotyped. They decline in situations of distraction and relaxation, while they increase under
stress and anxiety. It is generally preceded by premonitory urges or a sense of inner tension that is
reduced or relieved by the performance of the tic (Kwak et al., 2003). Motor tics can be classified
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as (i) simple, involving single muscle or small group of muscles
such as the case of blinking, eye rolling, nose twitching; or
(ii) complex, requiring a coordinated pattern of movement or
sound like touching, squatting, jumping. In the case of vocal
tics, sniffing, throat clearing, snorting, gulping, and coughing are
classified as simple; while barking, making of animal noises, and
uttering strings of words are classified as complex (Robertson,
2012). The most common manifestation is the eye blinking,
which is often the first to appear as well. The typical age of
onset ranges from 2 to 21 years with a mean at 7 years. Tourette
Syndrome is characterized by a waxing and waning course, peak
symptom intensity is usually noted in late childhood. The decline
of symptoms is usually in late adolescence or early adulthood
(Fusco et al., 2006; Stillman et al., 2009).
THE GENETIC BACKGROUND OF
TOURETTE SYNDROME
Like many other neuropsychiatric disorders, TS also has a
complex etiology. Several environmental risk factors have been
identified, such as perinatal hypoxia, maternal smoking during
pregnancy, exposure to androgens, heat, and fatigue (Swain
et al., 2007). These environmental factors may interact with
many underlying genetic risk factors. To assess the overall
genetic contribution in developing a disorder or trait, heritability
estimates can be determined, which usually vary between
different studies. Based on a recent meta-analysis of all human
twin studies to date, the heritability of tics/tic disorders is 0.45
(Polderman et al., 2015). The two most recent studies on the
heritability of TS and tic disorders estimated them to be 0.58 and
0.77, respectively (Davis et al., 2013; Mataix-Cols et al., 2015).
The risk for first-degree relatives was significantly higher than for
second-degree relatives (odds ratios 18.7 and 4.6, respectively).
Despite this relatively large overall genetic contribution, most
individual gene variants have only very small effects. Hence,
most of the earlier studies attempting to unravel the genetic
architecture of TS have been hampered by low statistical power
due to small sample sizes and clinical heterogeneity. Linkage
and candidate gene association studies have identified a number
of chromosomal regions and gene polymorphisms possibly
implicated in Tourette Syndrome. The candidates for these small
scale studies have traditionally been variations in genes involved
in the dopaminergic and serotonergic neurotransmitter systems,
generally due to their suspected contribution to the etiology
of other psychiatric disorders often comorbid with TS, such as
ADHD, OCD, autism, etc.
The studied genetic variations are classified in different
categories based on the extent of DNA alteration, including
single nucleotide polymorphisms (SNPs), as well as shorter
or longer repeat variants, such as variable number of tandem
repeats (VNTRs) and copy number variations (CNVs). SNPs
are the most common form of genetic variation in humans.
A SNP represents the change of a single base-pair (bp) in
the individual’s DNA sequence. The frequency of a particular
SNP can vary from private mutations (i.e., only one individual
possesses the variation due to a de novo mutation) to very
common polymorphisms found in almost half of the population.
Millions of SNPs exist in an individual’s genome, however, most
of them are presumed to be neutral, but some may alter gene
expression or cause structural changes in the encoded proteins
(and other transcripts). Due to this, many SNPs are known to
be associated with various human traits and diseases. VNTRs
are polymorphisms in the genome where a short sequence of
nucleotides (usually up to 100 bp) is organized in multiple
copies, which are clustered together and oriented in the same
direction. The copy number can vary between individuals and
this may influence gene expression or protein structure. CNVs
representmuch larger genetic rearrangements (usually thousands
to millions of base-pairs in length) and therefore change the
copy number of genes within the region due to the deletion or
duplication of a chromosomal segment. Gene variants implicated
in TS are summarized in Tables 1, 2.
Most genetic findings implicated in the pathogenesis of
Tourette Syndrome to date are inconsistent and studies yielding
positive results lack replication in other independent cohorts.
On the other hand, some nominally significant candidate gene
associationsmight suffer from lack of proper statistical correction
for multiple testing (e.g., Bonferroni correction). However, there
are some examples for positive replications as well, these are
summarized in Table 1. During the recent years meta-analyses
confirmed the role of SLITRK1, NTN4, DRD2, DRD4 and
AADAC gene polymorphisms in TS (Liu et al., 2014; Paschou
et al., 2014; Yuan et al., 2015; Bertelsen et al., 2016). Here, we will
review most of the genes that have been consistently replicated
in TS. Single positive findings are summarized in Table 2 and are
not discussed in detail.
SLITRK1 is a member of the SLIT and TRK family, a type-I
transmembrane protein with an extracellular leucine-rich repeat
domain homologous to SLIT (Aruga and Mikoshiba, 2003). It is
involved in the control of neurite outgrowth and it is expressed
during both embryonic and postnatal development of the cortex,
thalamus and the basal ganglia, the neuroanatomical structures
believed to be affected in TS (Proenca et al., 2011). The gene
coding for SLITRK1 is one of the most studied in relation with
Tourette Syndrome. In 2005, a de novo inversion at chromosome
13q33.1 and two additional rare variants were identified in TS
patients in the region including a single nucleotide deletion
causing a frameshift and a truncated protein and a mutation
in the 3′ untranslated region (3′UTR) at the putative binding
site for microRNA hsa-miR-189 (Abelson et al., 2005). Since the
original discovery several studies in various populations have
attempted to replicate the association with controversial results.
In a family study of Canadians, a common variation rs9593835
and two haplotypes were found to be associated with the disorder
(Miranda et al., 2009). These results were also confirmed in a
large sample of European trios with TS (Karagiannidis et al.,
2012). A recent study on SLITRK1 found a significant difference
in the distribution of haplotypes consisting of SNPs rs9546538,
rs9531520, and rs9593835 between Japanese patients and controls
(Inai et al., 2015).
Only one genome-wide association study (GWAS) has been
published to date in TS by a large international consortium
including a sample of 1285 cases and 4964 ancestry-matched
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controls (Scharf et al., 2013). After correction formultiple testing,
none of the half a million studied SNPs reached genome wide
significance (p < 5∗10−8), however top hits were enriched for
gene variants expressed in the brain and some of them coincide
with previous candidate genes. The top hit was rs7868992 (p
= 1.85∗10−6), which is located in an intronic region of the
COL27A1 gene (collagen, type XXVII, alpha 1). COL27A1 is a
fibrillar collagen primarily expressed in cartilage, but it is also
expressed in the cerebellum during several stages of human
development (Pace et al., 2003), however, its function in the
developing nervous system is unknown (Fox, 2008). Another
study in 260 Chinese trios assessed the preferential transmission
of the rs7868992 and two other COL27A1 gene variants
(rs4979357 and rs7868992) by transmission disequilibrium test
(TDT) and found the latter two variants nominally significant,
however these results did not survive correction for multiple
testing (Liu et al., 2015b).
A replication study with the top 42 SNPs of the original GWAS
was performed with a sample of over 600 cases and 600 controls
and the meta-analysis yielded a top signal at rs2060546 with p =
5.8∗10−7 in proximity of the NTN4 gene on chromosome 12q22,
which codes for netrin 4, an axon guidance protein expressed in
the developing striatum. Many of the previous findings (26 out
of 42) showed a similar trend underlining the reliability of the
GWAS hits as true risk factors for TS (Paschou et al., 2014).
Dopamine receptors, especially DRD2 and DRD4 are two
of the most widely studied candidate genes in the field of
psychiatric genetics. The dopamine D2 receptor (DRD2) located
on chromosome 11p23.2 was characterized previously with
TaqIA, TaqIB and TaqID SNPs based on restriction digestion of
these polymorphic sites with the TaqI restriction endonuclease
enzyme (Vereczkei et al., 2013). Later it turned out that the
TaqIA cleavage site is located ∼10 kilobases downstream from
the DRD2 gene, in exon 8 of the ANKK1 (ankyrin repeat and
kinase domain containing 1) gene (Neville et al., 2004), which
is a member of the serine/threonine kinase family. The TaqIA
polymorphism (rs1800497) causes an amino acid change in
ANKK1 (Glu713Lys), which seems to have a significant effect
on the specificity of substrate binding. The protein product of
the ANKK1 gene was considered as a negative regulator of the
transcription factor NF-kB (Nuclear Factor-Kappa B) (Meylan
and Tschopp, 2005). Moreover, the expression levels of NF-kB-
regulated genes were shown to be altered by the TaqIA variant
in an in vitro luciferase system (Huang et al., 2009). Since DRD2
is regulated by NF-kB (Fiorentini et al., 2002; Bontempi et al.,
2007) it could be assumed that this ANKK1 variant can indirectly
affect DRD2 receptor density. It is also possible, however, that the
TaqIA SNP is only a marker of other functional DRD2 variants
associated with a number of psychiatric disorders, such as the
strongly linked TaqIB (Ponce et al., 2009).
A recent meta-analysis on the association of the TaqIA SNP
rs1800497 and TS based on a number of previous case-control
studies (Table 1) comprising a sample of over 500 cases and 500
controls, as well as TS trios concluded that this variant is indeed a
risk factor for the development of the disorder (Yuan et al., 2015).
Another widely studied polymorphic dopamine receptor is
thedopamine D4 receptor gene (DRD4) The DRD4 gene located
on chromosome 11p15.5 is highly polymorphic, containing over
200 SNPs and several VNTRs. A 48 bp long VNTR ranging
from 2 to 11 repeats in exon 3 of the gene changes the length
of the third intracellular loop of the receptor (Vereczkei et al.,
2013) with a possible effect on downstream signaling efficiency
by inhibiting the adenylyl cyclase enzyme (Van Tol et al., 1992).
The DRD4 7 repeat allele seems to show decreased sensitivity to
dopamine compared to the 4 repeat allele (Asghari et al., 2002)
and according to more recent neurobiological findings it does
not form heteromers with D2 receptors in the striatum (Borroto-
Escuela et al., 2011). The D4 receptor is mainly expressed in
cortical and limbic regions in the CNS and carriers of the 7
repeat allele were shown to have higher susceptibility to various
addictive behaviors, ADHD, as well as several other psychiatric
traits.
A number of candidate gene studies have addressed the issue
of possible relevance of the exon 3 VNTR in DRD4 in TS,
and a couple of small family studies have found a positive
association (Table 1). A combined family and case-control study
in a Han Chinese TS population revealed significant transmission
disequilibrium for the 2 repeat and the 7 repeat alleles. The results
suggest that the 2 repeat allele might play a protective role, while
the common 4 repeat may predispose to TS (Liu et al., 2014).
Arylacetamide deacetylase (AADAC) is an enzyme involved
in neutral lipid lipolysis, detoxification, and drug metabolism
and is mainly expressed in the liver (Quiroga and Lehner, 2011).
However, its expression in different brain regions has also been
confirmed with a so far unknown physiological relevance. A
recent CNV-analysis in a smaller Danish TS cohort followed by
a meta-analysis of a large European sample of over 1000 TS
patients and 100,000 controls confirmed the role of AADAC
deletions in TS pathogenesis (Bertelsen et al., 2016).
The IMMP2L gene located on chromosome 7q31 encodes
a protein involved in processing the signal peptide sequences
used to target mitochondrial proteins into the mitochondrium.
Its association with TS was first discovered in a family with
a balanced 7;18 translocation (Boghosian-Sell et al., 1996). A
recent CNV study in a Danish cohort of 188 TS patients
reported a 5′-end intragenic deletion of IMMP2L in seven of
these patients (Bertelsen et al., 2014). Interestingly, in 4 of the
7 cases, the deletion was within intron 3. The frequency of
this IMMP2L deletion was significantly higher than that of the
control population. Notably, IMMP2L has been implicated in
other neuropsychiatric disorders, such as autism and ADHD
(International Molecular Genetic Study of Autism Consortium,
1998; Elia et al., 2010).
Histidine Decarboxylase (HDC), located on chromosome
15q21.2, encodes a member of the group II decarboxylase
family that converts the amino acid L-histidine into histamine,
a biogenic amine that can act as a local mediator released
from mast cells during an immune reaction, as well as a
monoaminergic neurotransmitter in the CNS. A premature
termination codon (W317X) in the HDC gene was discovered in
a large multigenerational family, where the father and all eight
of his children were affected with TS had the non-sense variant
(Ercan-Sencicek et al., 2010). On the other hand, a study of 100
Han Chinese TS patients failed to confirm the association of this
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non-sense mutation in HDC with the disorder (Lei et al., 2012).
However, a subsequent large family study of 520 European trios
with Tourette Syndrome transmission disequilibrium test (TDT)
found SNPs rs854150 and rs1894236 to be over-transmitted in
patients, confirming the role of HDC in the development of TS
(Karagiannidis et al., 2013). Interestingly, HDC knockout mice
have also been proposed as a genetic animal model of TS. The KO
animals exhibited potentiated tic-like stereotypies, recapitulating
a core phenomenology of the disorder (Castellan Baldan et al.,
2014; Xu et al., 2015).
The NRXN1 gene located on chromosome 2p16.3 codes for
an important mediator of cell-cell interactions in the central
nervous system and it has been implicated in neuropsychiatric
disorders, such as autism and schizophrenia (Vrijenhoek et al.,
2008; Glessner et al., 2009). A rearrangement of ∼400 Kb within
exons 1-3 of NRXN1 was recently found in TS patients (Nag
et al., 2013). Notably, this result is also consistent with a previous
analysis reporting the presence of a CNV comprising NRXN1 in
a Danish TS cohort (Sundaram et al., 2010).
For a more detailed review on the genetic background of
TS and the description of candidate genes where no positive
replications were published in the last few years, such as BTBD9,
SLC6A3 (DAT1) and MAO-A, see recent review papers by
(Paschou, 2013; Pauls et al., 2014).
FROM GENETICS TO EPIGENETICS
As described in the previous section, etiology of Tourette
Syndrome has a considerable genetic component. However,
it is evident that environment also plays an important role
in TS, since discordance between monozygotic twins is not
rare, while both prenatal (smoke, alcohol abuse, low birth
weight, etc), and perinatal (complicated birth) risk factors were
reported. Furthermore, it has also been hypothesized that TS
might arise as a consequence of autoimmune mechanisms
following Group A β-hemolytic streptococcal infection (GABHS)
(Swedo et al., 1998; Snider and Swedo, 2003), a condition
labeled as pediatric autoimmune neuropsychiatric disorder
associated with streptococcal infection (PANDAS). Finally, the
course of the disease is also influenced by environmental
factors.
As seen earlier, based on family and twin studies the
heritability of TS lies approximately between 50 and 80%, which
is a figure often seen in case of other psychiatric disorders.
However, gene polymorphisms reported by association studies of
these disorders rarely account for more than just a fraction of the
overall estimated genetic variance. This phenomenon of “missing
heritability” may, in part, be explained by various epigenetic
mechanisms arising from the dynamic interaction between the
environment and an individual’s genome.
Cells are reacting to acute and chronic environmental
changes by altering their gene expression state, which can be
considered as their adaptive reaction. The first step in this
adaptive reaction is the modification of the chromatin structure.
Chromatin is the macromolecular complex containing DNA
and nuclear proteins/histones. The nucleosome is the building
unit of chromatin. It consists of two of each of the four core
histones (H3, H4, H2A, and H2B) forming an octamer wrapped
around twice by DNA (Figure 1). The positively charged N-
terminal histone tails are prone to undergo several modifications
(acetylation, methylation, phosphorylation, etc.). Similarly, DNA
can be methylated. These covalent modifications influence the
chromatin structure and lead to changes of the transcriptional
state of genes. Even though these changes are dynamic, they can
be maintained through cell divisions and from one generation
to the next. This mechanism, which does not involve the
DNA sequence, but allows the transmission of acquired traits
through mitosis and sometimes through a few generations, is
called epigenetic inheritance. Another main but chromatin-
independent epigenetic mechanism is via non-coding RNAs,
which also play a crucial role in gene expression regulation often
together with chromatin-related mechanisms.
EPIGENETIC MODIFICATIONS
DNA Methylation
The most common epigenetic modification of DNA is the
covalent attachment of a methyl group to the C5 position of
cytosines. In mammals methylation occurs almost exclusively
in CpG dinucleotides (Ziller et al., 2011). Most of the CpG
dinucleotides of the genome are present in regions with low GC
abundance (Bird, 1993). These CG dinucleotides are generally
methylated in all cell types. Methylation leads to high mutation
rate, since the frequent oxidative deamination of 5-methyl-
cytosine (5 mC) results in thymine (Antonarakis et al., 2000;
Baba et al., 2011). This mutation is inefficiently repaired and
thus its transmission rate is high. Therefore, low CpG frequency
(10% of the expected) characterizes the non-coding part of
the genome and CpG cytosines progressively disappear from
these genomic regions. However, short CpG-rich sequences
(CpG islands – CGI) are frequently found in gene regulatory
regions (Bird et al., 1985; Deaton and Bird, 2011). CGIs often
show tissue-specific methylation pattern and are frequently
unmethylated (only) in germ cells (Smallwood et al., 2011; Zeng
et al., 2014). Thus, the important gene regulatory sequences are
preserved from a high mutation rate maintaining their biological
function.
DNA methylation is tightly linked to gene expression.
The more a regulatory region is methylated the less the
gene is expressed. Several gene expression regulating DNA
binding proteins (e.g., transcription factors) are sensitive to the
methylation of their target sequence. Some of them cannot
bind if the sequence is methylated (e.g., CTCF, E2F family,
Myc, CREB; Hark et al., 2000; Blattler and Farnham, 2013),
while others require methylated DNA for binding (e.g., MeCP2
methyl-CpG-binding protein 2 or Kaiso, a zinc finger protein;
Lewis et al., 1992; Prokhortchouk et al., 2001; Arányi et al.,
2005; Smith and Meissner, 2013). By the stabilization of
different chromatin states, DNA methylation contributes to cell
differentiation, cellular memory, X chromosome inactivation,
and other nuclear processes. Although initially it was considered
to be a static epigenetic mark, DNA methylation dynamically
changes (Kangaspeska et al., 2008; Métivier et al., 2008; Yamagata
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FIGURE 1 | Overview of common covalent epigenetic modifications. A schematic nucleosome and examples of potential epigenetic modifications are shown.
The histone octamer is represented in a cylindrical form with one pair of histones H3/H4 indicated. The protruding H3 histone tail and DNA are indicated in orange and
purple, respectively. Oppositely, histone and DNA modifications are shown in purple and orange. The functional roles of histone modifications are indicated in colored
boxes. The enzyme families catalyzing the modifications are listed in boxes below. The enzymatic links between the different cytosine modifications are shown in the
upper right corner of the figure.
et al., 2012b) and different enzymes ensure the equilibrium
state.
DNA methylation is catalyzed by DNA methyl-transferase
(DNMT) enzymes, which either establish or maintain the
methylation pattern. DNMT1 is a maintenance methyl-
transferase and it preferentially methylates DNAmethylated only
on one strand in order to preserve and reestablish the pattern
of methylation after DNA replication (Pradhan et al., 1999;
Mohan and Chaillet, 2013). By doing so, during DNA replication
DNMT1 is enriched at the replication fork and reproduces
the methylation pattern based on the original template strand
(Schermelleh et al., 2007). DNMT3A and DNMT3B are de
novo methyl-transferases capable of establishing new patterns
of methylation. DNA demethylation is mainly performed by
members of the ten-eleven-transferase (TET) enzyme family
through the hydroxylation of the methyl group. This leads to the
formation of 5-hydroxymethyl-cytosine (5 hmC), which is lost
after further oxidation by the same enzyme (Hashimoto et al.,
2015). While 5 mC nucleotides represent a few percent (typically
between 3 and 7%) of all genomic cytosines in cells and cell lines,
5 hmC is much less abundant constituting only 0.01–1% of all
cytosines (Globisch et al., 2010). Interestingly, 5 hmC is rather
frequent in primary cells and particularly in the brain (Globisch
et al., 2010). Different data also indicate that 5 hmC does not
have a general transcriptional repression effect as 5mC does (Wu
et al., 2011; Kang et al., 2015; Li et al., 2016).
During development, genome-wide methylation changes
occur before the differentiating cells acquire the adult-type
methylation profiles. Similarly, induction of pluripotent stem
cells or differentiation of stem cells in their physiological niches
is accompanied by general DNA methylation changes. It is
a dynamic and lifelong feature of DNA methylation. Local
methylation changes happen in response to environmental
factors, such as hormonal and metabolic effects or even early
childhood stress (see later). The affected genes are silenced
for long periods potentially through several generations. Toxic
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molecules, infections and hereditary or acquired diseases can
have similar effects (Yamagata et al., 2012a). However, these
alterations can undergo rapid reversion under appropriate
environmental conditions. Due to the different environmental
factors acting on each individual separately, DNA methylation
changes throughout aging generate increasing methylation
pattern differences between monozygotic twins, which leads to
progressively appearing phenotypical variability (Fraga et al.,
2005).
Histone Modifications
Histones are small, globular proteins, which are highly conserved
in all eukaryotes. As mentioned earlier, the core histones building
up the nucleosomes have N-terminal protruding tails, which
are particularly prone to undergo posttranslational modifications
(Allfrey et al., 1964). These epigenetic modifications include
acetylation, methylation and phosphorylation. They play an
important role in different nuclear processes, such as replication,
DNA repair, transcription, and chromatin structure stabilization
(Kouzarides, 2007; Bannister and Kouzarides, 2011). Although
it was reported several decades ago that histones might undergo
covalent modifications, their intensive investigation started only
in the late 1990s.
The initial studies identified the lysine residues as targets
of acetylation and revealed that they are essentially located on
the H3 and H4 histone N-terminal tails. These modifications
have rapid turnover (Zee et al., 2010). The reactions are
catalysed by a high number of histone acetyl-transferases (HAT)
and histone deacetylases (HDAC and Sirt) (Kuo and Allis,
1998; Legube and Trouche, 2003). Some complexes with HAT
activity (e.g., p300 and CBP–CREB-binding protein) recruit also
transcription factors and RNA PolII (Sakamoto et al., 2004).
Thus, not surprisingly, lysine acetylation marks transcriptionally
active euchromatic gene regulatory regions. For example, H3K27
(lysine 27 of histone H3) acetylation identifies active regulatory
elements and separates active and inactive enhancers (ENCODE
Project Consortium, 2012). H4 acetylation also indicates active
chromatin territories; the acetylation of the two histones often
occurs simultaneously. Acetylation profiles are inherited during
DNA replication. Themolecularmechanisms are still unclear and
there might be several. According to one of them, histones with
their epigenetic modifications are randomly distributed between
the two newDNAmolecules while the new chromatin is forming.
Than newly synthesized histones are deposited and they rapidly
acquire similar modifications to the old ones (Budhavarapu et al.,
2013).
After understanding the role of histone acetylation, studies
on histone methylation begun. Histone methylation has a much
more complex pattern than acetylation since both arginines
and lysines can be modified. Furthermore, arginines can be
mono- or di-methylated, while lysines can be mono-, di-, or tri-
methylated (Bannister and Kouzarides, 2011; Jahan and Davie,
2015; Greenblatt et al., 2016). Dozens of enzymes catalyse these
post-translational modifications and their removal. The different
enzymes are very selective and are capable to catalyse only one
or two specific reactions (such as mono- and di-methylation
of a specific lysine but not tri-methylation). Different histone
methylations are specifically associated with various gene or
chromatin regions. For example, H3K4me3 (trimethylation of
lysine 4 of histone H3) marks transcription start sites (TSS) and it
is characteristic of active promoters in the euchromatin (Santos-
Rosa and Caldas, 2005). In addition, H3K36me3 is associated
with actively transcribed gene bodies (Edmunds et al., 2008),
while H3K27me3 typically occurs in transcriptionally repressed,
heterochromatic regions (Bracken et al., 2006).
Networks of Epigenetic Modifications
In the different chromatin regions, complex patterns of histone
and DNA modifications co-occur, which led to the formulation
of the “histone code” hypothesis (Jenuwein and Allis, 2001).
According to this hypothesis distinct patterns of chromatin
modifications at any given genomic region would have the same
meaning. These patterns are read by specific proteins, which then
execute their local roles accordingly. However, it turned out that
the histone code is most probably highly redundant.
Still, the epigenetic modifications are recognized by chromatin
binding proteins. These proteins then often antagonize or
promote the removal or catalysis of other covalent marks
leading to the formation of complex patterns (Bannister and
Kouzarides, 2011). Other proteins sensitive to the epigenetic
pattern play important role in nuclear processes (e.g., γH2AX,
a phosphorylated histone, participating in DNA repair). The
proteins sensing and modifying the epigenetic marks are called
readers, writers or erasers. Certainly, these proteins bind the
chromatin with different affinity and therefore, they reside
there for a shorter or longer time period depending on the
local environmental context. The networks of modifications are
therefore stochastically self-assembling and disassembling with
various probability depending on the environmental conditions
(Jeltsch and Jurkowska, 2014). This rapidly changing feature of
the network makes the system particularly efficient in reacting
to environmental stress (e.g., starvation, oxidative stress, or
viral infection (Yamagata et al., 2012a) and modulating gene
expression states in order to maintain the cellular homeostasis.
Therefore, it is not surprising that enzymes catalysing the
addition or removal of covalent post-translational modifications
of histones and DNA are closely linked to intermediary
metabolism (Figure 2). To acetylate lysine residues, HAT
enzymes use acetyl-CoA, a key molecule in carbohydrate and fat
metabolism. Class III histone deacetylases (Sirt) need NAD+ for
their activity (Vaquero et al., 2007). High level of energy intake
leads to hyperacetylated histones, while low energy intake favors
histone hypoacetylation. Methylation of histones and DNA needs
S-adenosyl-methionin (SAM) as a cofactor, the methyl donor
in biochemical reactions. The reaction also needs folate to
regenerate SAM. The TeT (Ten-eleven Translocase) enzymes
are oxygenases, which catalyse the demethylation reaction of
DNA through the formation of 5-hydroxy-methyl cytosine.
Jumonji family of histone demethylases have a similar reaction
mechanism (Chen et al., 2006). Both TeT and Jumonji enzymes
use α-ketoglutarate as a co-factor, which is a key metabolite of
the citric-acid cycle. Enzymes catalysing the formation of α-
ketoglutarate are different isoforms of isocitrate dehydrogenase
(IDH). Some of the IDHs are mitochondrial, others are cytosolic,
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FIGURE 2 | The relationship between epigenetic modifications and intermediary metabolism. Glycolysis, lipid metabolism, citric acid cycle, amino acid
metabolism, and folate/SAM cycles are tightly linked to epigenetic modifications (shown in the middle), since their products and cofactors (shown in red) are
substrates of enzymes catalyzing the epigenetic modifications. Acetyl-coenzyme A and NAD contribute to histone acetylation and deacetylation, respectively. Methyl
groups and alfa-ketoglutarate participate in the methylation and demethylation of both histones and DNA. NAD: nicotinamide adenine dinucleotide, THF:
tetrahydrofolate, SAH: S-adenosylhomocysteine, SAM: S-adenosylmethionine.
and they depend on NADP and NAD, respectively. SNPs of these
enzymes are associated with TS (see later), while their mutations
show frequent occurrence in tumors (gliomas, AML) (Dang
et al., 2010). The gain-of-function mutant enzymes catalyse the
formation of 2-hydroxyglutarate (2-HG), a potent inhibitor of
demethylases. Altogether these data suggest a tight link between
environmental factors and epigenetic modifications.
Non-coding RNA(ncRNA)
Evidence from the Encyclopedia of DNA Elements (ENCODE)
suggests that at least 80% of our genome is transcribed.
The human genome encodes for less than 3% of protein-
coding transcripts and consists primarily of the non-coding
RNAs (ncRNAs), which was previously regarded as “junk”
DNA (https://www.encodeproject.org/). Non-coding RNAs play
a role in gene expression regulation (see below). For example
they are implicated in the regulation of genes coding for
enzymes catalyzing epigenetic modifications. Furthermore,
non-coding RNAs are also involved in the regulation of
chromosomal domains in tight interaction with epigenetic
covalent modifications (e.g., X-chromosome inactivation).
An arbitrary threshold of 200 nucleotides of transcript length
was drawn to classify two groups of ncRNAs into small or long
ncRNAs. Small ncRNAs include microRNAs (miRNA), transfer
RNAs (tRNA) and small nucleolar RNAs (snRNA). A microRNA
(miRNA) is a small non-coding RNA molecule found in plants,
animals and some viruses, which functions in transcriptional and
post-transcriptional regulation of gene expression.
The biogenesis of microRNA involves two different cleavage
steps by protein complexes taking place in the nucleus and in
the cytoplasm leading to the development of an ∼22 nucleotide
long mature single-stranded miRNA (Figure 3; Filipowicz et al.,
2008). First, the gene coding for miRNAs is transcribed by
RNA Polimerase II resulting in a long precursor pri-miRNA
characterized by a hairpin or fold-back structure with an
imperfectly base-paired stem and a terminal loop (Miyoshi
et al., 2010). Then, the hairpin structure of the pri-miRNA
is cleaved and the ∼70 nucleotide long precursor called pre-
miRNA is released (Miyoshi et al., 2010). Subsequently, the pre-
miRNA is exported into the cytoplasm (Kim et al., 2009). Once
in the cytoplasm, the pre-miRNA is processed by RNase III
Dicer generating a∼22 nucleotide miRNA-miRNA∗duplex. One
strand of the duplex is loaded into a large multi-protein miRNA
ribonucleoprotein complex (RISC complex), while the other
strand, “passenger,” is degraded. Once incorporated into RISC,
the miRNA guides the complex to its messenger RNA targets
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FIGURE 3 | miRNA biogenesis. MicroRNA (miRNA) genes are transcribed as primary miRNAs (pri-miRNAs) by RNA polymerase II (Pol II) in the nucleus. The long
pri-miRNAs are cleaved by Microprocessor, which includes DROSHA and DiGeorge syndrome critical region 8 (DGCR8), to produce precursor miRNAs (pre-miRNAs),
which are then exported to the cytoplasm by Exportin 5 and further processed by the DICER/TRPB complex to produce an miRNA duplex. One strand of the mature
miRNA (the guide strand) is loaded into the miRNA-induced silencing complex (RISC) mediating gene suppression by targeted mRNA degradation or translational
repression.
by base-pairing interactions. The binding to the miRNA target
relies on the seed sequence, a 6–8 nucleotide domain located
at the 5′ end of the miRNA. Based on the complementarity of
the seed sequence and the target mRNA sequence located in the
3′UTRof the transcript, miRNAs down-regulate gene expression
either through translational repression or mRNA degradation
(Hutvágner and Zamore, 2002).
Longer RNAs include ribosomal RNAs (rRNA), natural
antisense transcripts and other long non-coding RNAs
(lncRNAs). Currently, about 2500miRNAs and 50,000 lncRNAs
have been annotated in the human genome, besides the ∼19,000
protein coding genes. As opposed to miRNAs, only a few
lncRNAs show evolutionary conservation of the primary
sequence, but most of them show tissue and cell type-specific
expression, indicating that their expression must be tightly
controlled. LncRNAs exhibit a diversity of molecular functions:
they can act as transcriptional activators or repressors, as
scaffolds for protein-protein interactions or as molecular decoys.
Genetic polymorphisms can involve both ncRNA sequences
throughout the genome, as well as sequences in their target genes,
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which can affect ncRNA-mediated regulation. Polymorphisms in
ncRNA genes can influence both their level of expression and the
ncRNA function, thus resulting in differential regulation of their
target genes.
Genetic variation may affect miRNA-mediated regulation in
different ways. Altered miRNA transcription can be a result
of polymorphisms in (a) miRNA promoters, (b) splice sites of
the host gene where miRNAs reside, since many miRNAs are
intronic, or (c) of polycistronic miRNA clusters (Calore et al.,
2015). Mutations in the sequence of the transcribed miRNA may
change its binding affinity to the biogenesis enzyme complexes,
which changes their processing and may lead to misregulation of
target genes. IsomiRs are variants within the processed miRNA
sequence, which can affect specificity to their target, on the other
hand target messenger RNA 3′UTR variants may either destroy
existing miRNA seed regions or create new recognition sites.
The presence of a SNP in the 3′UTR can theoretically result in
three alterations in miRNA related regulation: (a) it can partially
or completely disrupt the miRNA binding site, thus resulting in
higher expression of the target gene, or (b) more rarely a SNP
could either enhance the binding of a miRNA to the 3′UTR
region through improvement of the original recognition site
or (c) it may create a novel binding site for another miRNA.
The latter will only affect the expression of the target gene if it
coincides with the expression of the new miRNA spatially and
temporally.
Although lncRNAs possess a much lower degree of
conservation than miRNAs, their genetic polymorphisms
may still be functional, i.e., SNPs within the lncRNA loci can
change their expression or influence their downstream target
genes. Altering lncRNA architecture may influence its ability to
interact with proteins or other RNAs. In recent years, genetic
variations in lncRNAs were implicated in several human diseases.
EPIGENETICS OF NEUROPSYCHIATRIC
DISORDERS
Epimutations are epigenetic alterations, which have been
linked to several diseases. These alterations can be classified
as primary or secondary based on their origin (Oey and
Whitelaw, 2014). Primary epimutations seem to be due to only
environmental stress factors. It is often difficult to understand
the pathomechanism of the resulting diseases or traits, which are
generally less severe than in the case of secondary epimutations.
Secondary epimutations are due to an initial genomic mutation.
Most of these mutations target readers, writers and erasers of the
epigenetic system and can lead to important changes of the global
epigenetic profile (Lopez-Atalaya et al., 2014). In the following
section we will describe some examples of epimutations leading
to neuropsychiatric disorders (Plazas-Mayorca and Vrana, 2011).
Rubinstein-Taybi Syndrome
Rubinstein-Taybi syndrome has various clinical signs including
moderate to severe learning difficulties (for a recent review see
Lopez-Atalaya et al., 2014). The hereditary disease is autosomal
dominant although very few documented cases of transmission
exist. Most of the patients have de novo mutations. The
development of the syndrome can be attributed to mutations in
the CREB-binding protein (CBP) or more rarely in the highly
homologous p300 protein encoding genes. Both proteins are
transcriptional co-activators, have HAT activity and they bind the
acetylated histones via their bromodomain. Thus, they provide
platforms for other proteins (transcription factors and RNA
PolII) necessary for transcription initiation.
Gliomas
Gliomas (Vigneswaran et al., 2015) are tumors arising from
glial cells in the central nervous system (CNS). During
tumor progression patients experience psychiatric, cognitive,
and neurologic symptoms (Boele et al., 2015). Primary low-
grade gliomas are typically diagnosed in the 40 s, and after
treatment, these slow-growing tumors have a tendency to
reappear and progress in grade to become grade III gliomas
or glioblastomas (grade IV). In contrast to the secondary
high-grade glioblastomas, the primary high-grade glioblastomas
are diagnosed later and have very poor prognosis. Although
histologically identical, the primary and secondary glioblastomas
have different molecular characteristics.
Both primary low-grade and secondary high-grade
gliomas are characterized by IDH1/2 mutation (see above).
Approximately 90% of the mutations occur in the IDH1 gene
and almost all of them are the R132H variant (Vigneswaran et al.,
2015). As mentioned earlier, this enzyme variant catalyzes the
formation of an oncometabolite (2-HG), which inhibits DNA and
histone demethylation leading to general (secondary) alteration
of the epigenetic profile (Cohen et al., 2013). Nevertheless,
gliomas with mutated IDH1/2 gene have better prognosis than
the others (Andronesi et al., 2013).
Rett Syndrome
Rett syndrome is a disease affecting only girls (1:10,000–
15,000) (Chahrour and Zoghbi, 2007; Katz et al., 2012) and
it is characterized by early onset (18 months) and variable
neurological symptoms. Severe mental retardation and motor
impairment such as ataxia, apraxia, and tremor (Chahrour and
Zoghbi, 2007) accompanied by seizures and gastrointestinal
symptoms are frequently present (Katz et al., 2012). Rett
syndrome is an example of a severe disorder due to the mutation
of the MeCP2 gene encoding an epigenetic “reader” i.e., a
regulatory protein recognizing an epigenetic mark (Amir et al.,
1999). Therefore, although Rett syndrome is considered to be a
typical epigenetic disease, no major epigenetic alterations can be
observed in the patients. Loss-of-function mutations of the gene
coding for the transcriptional repressor MeCP2 are responsible
for the development of the disease (Amir et al., 1999). MeCP2 is
a member of the methyl-CpG binding domain (MBD) protein
family. Upon binding of methylated DNA, MeCP2 recruits
transcriptional repressor complexes and HDACs. Interestingly,
MeCP2 has recently been found to bind and repress long
genes implicated in neuronal differentiation and modulation of
neuronal functions (Gabel et al., 2015).
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Autism Spectrum Disorder (ASD)
Rett syndrome is also considered to be a rare form of autism
spectrum disorder (ASD) (Mbadiwe and Millis, 2013). ASD is
clinically characterized by social communication deficits and
repetitive behavior, which appears as early as 2 years of age
and causes clinically significant impairment. ASD has high
heritability rates suggesting a substantial genetic background. It
has a polygenic origin with hundreds of susceptibility genes.Most
of them are common variants with small effects, while some
rare de novo variants with large effects also exist (Loke et al.,
2015). Apart fromMeCP2, FMR1, and OXTR also have profound
effects and they were repeatedly reported in relation with ASD
(Mbadiwe and Millis, 2013). Both of them are also linked to
epigenetic alterations, which is clearly secondary in case of FMR1.
Fragile X syndrome
Approximately half of the patients with Fragile X syndrome meet
the criteria of autism and it is a relatively frequent cause of ASD
(5% of all monogenic cases). The FMR1 gene encodes FMRP,
a polyribosome associated protein playing an important role in
protein translation (Penagarikano et al., 2007). The absence of the
protein leads to perturbed neuronal development and intellectual
disability (Contractor et al., 2015). Fragile X syndrome is caused
by a CGG trinucleotide expansion in the regulatory region of the
FMR1 gene located on the chromosome X. This repeat expansion
(>200) leads to the attraction of DNA methylation and the loss
of expression of the gene (Oberlé et al., 1991; Penagarikano et al.,
2007).
The oxytocin receptor (OXTR) gene is also a candidate gene
for ASD (Loke et al., 2015). The neurotransmitter and hormone
oxytocin was found to play a role in anxiety, aggressive behavior,
and other neural functions. Several observations indicate that
OXTR plays a role in the development of ASD. For instance,
four SNPs in the gene were suggested to be associated with ASD.
Furthermore, several studies reported higher DNA methylation
level in patients than in controls in the promoter region of the
gene (Gregory et al., 2009; Jack et al., 2012; Ziegler et al., 2015).
Very important methylation increase (20–40%) was observed
both in temporal cortex and peripheral blood. This temporal
hypermethylation was also correlated with lower OXTR mRNA
levels in autists (Gregory et al., 2009). Thus, it is not surprising
that OXTRmethylation has been associated with anxiety disorder
and other traits characterizing ASD.
A recent genome-wide analysis of DNA methylation studied
a sample of 50 monozygotic (MZ) twin pairs including twins
discordant, as well as concordant for ASD. Within-twin and
between-group analyses identified a number of differentially
methylated regions associated with ASD. In addition, the authors
reported significant correlations between DNA methylation and
quantitatively measured autistic trait scores across the cohort
implicating a role for altered DNA methylation in autism (Wong
et al., 2014).
Finally, strong evidence shows that ASD has primary
epigenetic origin, as well (Tordjman et al., 2014). Children
with in utero exposure to the HDAC inhibitor valproic acid
(an anticonvulsive and mood stabilizer drug) were found in
several studies (Moore et al., 2000; Bromley et al., 2013;
Christensen et al., 2013) to have a significantly increased risk
to develop autism relative to those who were not treated. Other
environmental factors during pregnancy can be considered as
risk factors for ASD, such as viral infection (e.g., rubella) (Ornoy
et al., 2015) and the dietary folic acid supplementation, which is
regarded as controversial (Yang et al., 1989; Mbadiwe and Millis,
2013). Finally, several studies indicate that prenatal maternal
stress is also a risk factor for developing ASD (Kinney et al., 2008
and references therein).
A considerable number of studies indicate that early life
adversities (ELA) (e.g., childhood abuse or even prenatal and/or
maternal stress) are severe risk factors for the development of
psychiatric disorders such as major depression, suicidal behavior,
etc. (Hoffmann and Spengler, 2014; Palma-Gudiel et al., 2015;
Cattaneo and Riva, 2016). This seems to be due to a difficulty
in coping with stress in these patients. During stress reactions
the hypothalamus-pituitary-adrenal axis (HPA) is activated
and glucocorticoids (cortisol in humans and corticosterone)
are released, which in turn activate the pathways regulated
by glucocorticoid and mineralocorticoid receptors. The axis
is inhibited by the feedback activation of the glucocorticoid
receptor (GR) in the hippocampus (Palma-Gudiel et al., 2015;
Cattaneo and Riva, 2016).
The molecular mechanisms of the development of ELA-
related alterations have been deciphered in a rat model system
(Weaver et al., 2004).Weaver and colleagues have compared pups
from “good” nursing and “bad” nursing females, two maternal
behaviors generally occurring in rats (Liu et al., 1997; Caldji
et al., 1998). Offsprings of “good moms” were less fearful and
had a lower stress response in their adulthood than those of
“bad moms.” Weaver and colleagues observed higher DNA
methylation levels in the hippocampus from early childhood
(after postnatal day 1) until at least 3 months of age in the GR
promoter in the offsprings of “bad moms” relative to those of
“good moms.” This difference concentrated at a certain region
of the promoter and more precisely at a single CpG, located at
the binding site of transcription factor NGFI-A regulating GR
expression. They also observed the decreased binding of NGFI-
A and hypoacetylation of histones in the methylated region of
the promoter. These findings were accompanied by lower GR
expression. Interestingly, but not surprisingly for an epigenetic
mark, both the molecular and the behavioral phenotypes were
reversible. Treatment with Trichostatin A, an HDAC inhibitor,
reversed histone hypoacetylation, increasedNGFI-A binding, GR
expression, and decreased DNA methylation to some extent.
Similarly, changing the environment had a similar effect as shown
by cross-fostering, demonstrating that this phenotype is not
determined by the genetic background and should be considered
as having a primary epigenetic origin.
Based on these observations, several studies in animal models
confirmed these findings (McGowan et al., 2011). In human
cohorts a very small, but systematic methylation increase was
reported from the same region of the GR promoter in individuals
undergoing stressful events (Palma-Gudiel et al., 2015).
Non-coding RNAs are also associated with a wide range
of neurodevelopmental, neurodegenerative, and psychiatric
diseases both in humans and in animal models (Lin et al., 2011;
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Johnson, 2012; Talkowski et al., 2012; Ziats and Rennert, 2012;
Nishimoto et al., 2013; Petazzi et al., 2013; Barry et al., 2014).
As a recent example, genetic variants of the long non-coding
RNA MIAT were found to contribute to the risk of paranoid
schizophrenia in a Han Chinese population (Rao et al., 2015).
The authors performed a two-stage association analysis on 8
tagging SNPs covering the wholeMIAT locus in two independent
Han Chinese schizophrenia case–control cohorts. The discovery
sample with over 1000 cases and 1000 controls yielded a
significant increase of the minor T-allele of rs1894720 in patients
and this association was confirmed in the replication cohort of a
similar size.
MicroRNAs are also implicated in several neuropsychiatric
disorders, such as schizophrenia and autism (Beveridge and
Cairns, 2012; Mellios and Sur, 2012), neurodegenerative
disorders like Alzheimer’s and Parkinson’s disease (Salta and De
Strooper, 2012; Abe and Bonini, 2013; Tan et al., 2013), but also in
other neurodevelopmental disorders such as Fragile X syndrome
and Rett syndrome (Urdinguio et al., 2010; Wu et al., 2010; Im
and Kenny, 2012; Sellier et al., 2013).
Epigenetics of Tourette Syndrome
As described earlier, the studies investigating TS mainly focused
on the genetic background of the disease. Only few studies have
been performed to date to investigate the role of epigenetic
factors and non-coding RNA in the development of TS. One of
these identified a nucleotide variant (var321) in the 3′ UTR of
the SLITRK1 gene leading to its stronger repression by miR-189.
This variant has been investigated in several studies in Tourette
patients and reported to be rare (Abelson et al., 2005). However,
the role of this variant in TS pathogenesis is questionable due
to its very low frequency (Keen-Kim et al., 2006). The unique
study reported to date on the role of microRNAs in Tourette
Syndrome profiled the expression of 754 miRNAs in the sera of
six TS patients and three unaffected controls (Rizzo et al., 2015).
The study found that miR-429, which is involved in midbrain
and hindbrain differentiation and synaptic transmission was
significantly underexpressed in TS patients. Measurement of
circulating miR-429 may in the future be useful as a molecular
biomarker to aid TS diagnosis.
Two association studies on DNA methylation related to TS
have been conducted so far. The first showed no methylation
alteration in TS patients relative to controls in a region on
chromosome 8 in KCNK9 and TRAPPC9 genes (Sánchez
Delgado et al., 2014). The regions were identified recently
by genome-wide screens and by mapping mutations in single
families. The other study was the first Epigenome-Wide
Association Study (EWAS) investigating DNA methylation
differences between hundreds of controls and patients from
the Netherlands Twin Registry with tic phenotype (Zilhão
et al., 2015). Very small methylation differences were observed,
however, an enrichment of differentially methylated neural genes
previously linked to neuropsychiatric disorders or with brain
specific function was found among the top hits.
Finally, a recent promising study investigated GWAS results
on gene sets. The association of TS and a gene set related
to carbohydrate metabolism and more particularly a group of
33 genes involved in “astrocyte-neuron metabolic coupling,”
glycolysis and Krebs-cycle was demonstrated (de Leeuw et al.,
2015). This is interesting because the genes identified include
IDH2 (see above) and Malic enzyme 1, which is regulated
by glucose level. Since these TS associated metabolic genes
are known to play a role in epigenetic modifications, this
suggeststhat the disorder is potentially characterized by altered
neural epigenetic patterns.
Outlook
In the present review, we have shown that TS is a
neuropsychiatric disorder with significant heritability. However,
while very few rare genetic variants with large effects were
described, it is plausible to assume that hundreds or even
more frequent variants with small effects underlie the genetic
susceptibility of the disorder. Furthermore, a considerable
number of observations indicate that environmental factors
also play a crucial role in the development of TS. As introduced
above, environmental factors act via epigenetic modifications,
including heritable covalent modifications of the chromatin
and regulatory non-coding RNAs. In order to better understand
the pathomechanism of TS, we propose here that more studies
should be performed focusing on the role of epigenetics.
What questions should be asked? We think that since
environmental (risk) factors are implicated in TS, these should
be studied with particular interest. For instance, discordant
monozygotic twins are very good candidates for finding
epigenetic modifications implicated in the development of the
disease, since they are genetically identical. Similarly, patients
with known prenatal or perinatal antecedents probably also
have important epigenetic grounding in the development of
TS. We also consider that patients who developed TS due to
streptococcus infection should also show epigenetic alteration
relative to controls. Finally, since the disease is characterized by
waxing and waning, kinetic analysis of epigenetic changes might
also reflect important aspects of TS.
Animal models of TS or tic phenotype should also be studied
for epigenetic alterations. While studies on human cohorts might
be more descriptive, analyses of animal models could explain
more directly the underlying molecular mechanisms.
How should these questions be addressed? Currently several
techniques are available to study epigenetics. Genome-wide
analyses are much more informative than investigations of
single targets. These genome-wide approaches have recently
become much less expensive and therefore affordable for
most of the laboratories or consortia. Expression level
and GWAS analyses can be performed on ncRNA, while
chromatin immunoprecipitation (ChIP) followed by next
generation sequencing (NGS) is useful for the investigation of
histone modifications (Furey, 2012). Along with the ongoing
technological advances in NGS, identifying genetic variation
affecting ncRNA function associated with neuropsychiatric
disease is likely to grow rapidly.
Finally, several genome-wide techniques exist for the study of
DNA hydroxymethylation and DNA methylation. We propose
to study DNA methylation rather than histone modifications,
because it is more stable, than the latter one, although not as
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static as initially thought (Yamagata et al., 2012b). Furthermore,
ChIP-like antibody-based techniques are much less quantitative
than the chemical transformation (bisulfite conversion-based)
techniques developed for DNA methylation. Therefore either
array-based hybridization approaches after bisulfite conversion
[Illumina 450 k (Bibikova et al., 2011) or the recent 850 k
bead chips] or bisulfite conversion coupled to next generation
sequencing could yield useful information (Kulis et al., 2012).
What cautions should be taken? First, we consider that the
most important issues are sample size and tissue of origin. TS
is a psychiatric disease mainly due to alterations in neuronal and
potentially in glial cells. These cells in humans are rarely available
for research, while blood cells and buccal or nasopharingeal
epithelial cells have somewhat different epigenetic signatures.
Although some of these cells can have similar epigenetic
profiles in some genomic regions to the most important brain
regions in TS (e.g., striatum), the results should always be
interpreted cautiously (Hannon et al., 2015). In order to avoid
such problems, brain samples should be investigated when
possible, however that has obvious limitations in humans.
Alternatively, asmentioned before discordantmonozygotic twins
can also be studied, finally, patients with TS presumably due to
PANDAS origin are good candidates for blood sample analysis.
It is hard to determine the ideal sample size. However, it is
clear that already small sample sizes can be informative if
repeated experiments give similar results and the samples are
well-selected.
Second, new approaches available and proposed lead to the
generation of “big data.” Their correct analysis is necessary
and requires the intensive collaboration of the biomedical
and bioinformatitian scientists with profound knowledge of
statistics.
Finally, when interpreting data, attention and caution should
be exercised. Although biologically meaningful cutoffs for
methylation differences between patients and controls is hard
to determine, the value of very small but statistically significant
changes is questionable. Furthermore, statistically significant hits
showing association with the phenotype does not neccessarily
mean causality. From a single descriptive experiment causality
cannot be concluded, but further experiments should be
performed.
In conclusion, we consider that introducing epigenetic studies
in TS research has great potential. These investigations based
on the previous results, the animal models and the twin
and patients registries already existing will certainly identify
new molecular mechanisms and hits playing an important
role in the development of the disease. The discovery of
the molecular details of ncRNA and epigenetic modification
mediated regulation of gene expression, proteins and pathways
is likely to provide novel insights into the pathogenesis of
neuropsychiatric disease including Tourette Syndrome. This will
also open new avenues for genetic diagnosis, as well as targeted
and personalized therapeutic approaches. These studies will also
strengthen the importance of some already known and suspected
hits and altogether this will lead to the better understanding
of TS and the opening of new avenues for the development of
treatments.
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